SCHEMBL139417

SCHEMBL139417

[CH]=[C]C=C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27883313 0.67
SCHEMBL44197 0.67
SCHEMBL2884436 0.67
SCHEMBL27798770 0.63
Methane SCHEMBL22749558 0.63
Ethyne SCHEMBL7610107 0.63
SCHEMBL28285000 0.63
Acrylonitrile SCHEMBL3456649 0.60
Butadiene SCHEMBL10934316 0.60
SCHEMBL28072642 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 853 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240180941-A1 ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2024-06-06 US disclosed
US-20240182865-A1 VISIBLE LIGHT POLYMERIZATION OF POLYETHYLENE GLYCOL (PEG) HYDROGELS STEM PHARM, INCORPORATED 2024-06-06 US disclosed
EP-4377311-A1 2-DIAZO-3-OXO-2,3-DIHYDROSPIRO[INDENE-1,9'-XANTHENE] DERIVATIVES AND SIMILAR COMPOUNDS AS PHOTOACTIVE FLUORESCENT COMPOUNDS FOR PROTEIN LABELING Eikon Therapeutics Inc. (US) 2024-06-05 EP disclosed
US-11998610-B2 Conjugates and methods of using the same FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2024-06-04 US disclosed
US-11981703-B2 Polynucleotide constructs SIRIUS THERAPEUTICS, INC. (US) 2024-05-14 US disclosed
US-11813272-B2 Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2023-11-14 US disclosed
US-20230321083-A1 Inhibitors of GPR174 and Uses Thereof OMEROS CORP (US) 2023-10-12 US disclosed
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION 2023-09-14 US disclosed
US-20230273228-A1 Diagnostic Method and Compounds for the Treatment of Infections Caused by a Pathogen SOLUTEX GC, S.L. (ES) 2023-08-31 US disclosed
US-20230242567-A1 CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE SIRIUS THERAPEUTICS, INC. 2023-08-03 US disclosed
US-6348596-B1 NUCLEIC ACID HYBRIDIZATION ASSAYS; DNA SEQUENCE DETERMINATION PE CORPORATION (NY) 2002-02-19 US disclosed
WO-2001091758-A1 WATER-SOLUBLE AMIDE DERIVATIVES OF POLYENE MACROLIDES AND PREPARATION AND USES THEREOF INTRABIOTICS PHARMACEUTICALS, INC. (US) 2001-12-06 WO disclosed
EP-1144401-A2 THIOCHROMANOYL CYCLOHEXENONE DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2001-10-17 EP disclosed
EP-1141137-A1 WATER-SOLUBLE RHODAMINE DYES AND CONJUGATES THEREOF Applera Corporation (US) 2001-10-10 EP disclosed
EP-1135385-A1 THIOCHROMANOYLPYRAZOLONE DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2001-09-26 EP disclosed
WO-2001049790-A2 MOBILITY-MODIFYING CYANINE DYES APPLERA CORPORATION (US) 2001-07-12 WO disclosed
WO-2001032783-A1 WATER-SOLUBLE RHODAMINE DYES AND CONJUGATES THEREOF APPLERA CORPORATION (US) 2001-05-10 WO disclosed
US-6191278-B1 COMPRISING A RHODAMINE-TYPE PARENT RING HAVING ATTACHED TO THE XANTHENE C9 CARBON A PHENYL GROUP THAT IS SUBSTITUTED WITH CARBOXY OR SULFONATE GROUP, ONE TO THREE AMINOPYRIDINIUM GROUPS AND AN ALKYL- OR ARYLTHIO, AND OPTIONALLY OTHER GROUPS PE CORPORATION 2001-02-20 US disclosed
WO-2000035903-A2 THIOCHROMANOYL CYCLOHEXENONE DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2000-06-22 WO disclosed
WO-2000034270-A1 THIOCHROMANOYLPYRAZOLONE DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2000-06-15 WO disclosed